In this case series, patients were managed by a more advanced telemedicine system where CGM devices allowed for the collection of a high volume of glucose data, SIPs enabled the accurate confirmation of insulin dosing, software and diabetes data management platforms enabled the instantaneous and seamless integration of data available at the time of the encounter when needed, and convenient telemedicine options were utilized (VVC and/or secure messaging), which fostered more frequent contacts between HCPs and patients. This evidence concerns the gene INS and diabetes mellitus.